Physician
Preventive Medicine
Dr. Charles H. Hennekens Jr., MD
|
|
Give Review
Charles Hennekens works in the field of Preventive Medicine. He researched medicine at Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University has a rank of 18 in research and a 49 in primary care He has 1 awards "Fellow (FACC)". Charles H. Hennekens Jr. is a published physician. He has 101 papers published. The most current publication "Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias."
Publications
- Regular Physical Activity: Forgotten Benefits.
- Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias.
- Calcium and vitamin D supplementation: facts and myths.
- Increasing rates of advance care planning through interdisciplinary collaboration.
- Aspirin in the primary prevention of cardiovascular disease: Current knowledge and future research needs.
- Guidelines and guidance in lipid modification.
- Enhancing Trial Integrity by Protecting the Independence of Data Monitoring Committees in Clinical Trials.
- Prevention: Aspirin in primary prevention needs individual judgements.
- Treatment of diabetes mellitus: the urgent need for multifactorial interventions.
- Cardiovascular risks of cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs: necessary but not sufficient for clinical decision making.
- Utilization of Statins: Guiding Principles and the New United States Guidelines.
- Treatment of Low Back Pain: The Potential Clinical and Public Health Benefits of Topical Herbal Remedies.
- Hypothesis: cadmium explains, in part, why smoking increases the risk of cardiovascular disease.
- Emerging clinical challenges in the use of statins.
- High Frequencies of Negative Pretreatment Results Following Presumptive Antibiotic Treatment for Chlamydia and Gonorrhea.
- Aspirin in the Treatment and Prevention of Cardiovascular Disease: Past and Current Perspectives and Future Directions.
- Aspirin Increases Nitric Oxide Formation in Chronic Stable Coronary Disease.
- Leading avoidable cause of premature deaths worldwide: case for obesity.
- United States counties with low black male mortality rates.
- Mortality from Homicide among Young Black Men: A New American Tragedy.
- Calcium supplements and risk of myocardial infarction: a hypothesis formulated but not yet adequately tested.
- Aspirin in the Primary Prevention of Myocardial Infarction.
- Geographic variations in percutaneous coronary interventions and coronary artery bypass graft surgery among tennessee elders.
- Statistical association and causation: contributions of different types of evidence.
- Control of health care-associated infections (HAI): winning both the battles and the war.
- The Need for Increased Utilization of Statins After Occlusive Stroke.
- A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans.
- Increased Black-White disparities in mortality after the introduction of lifesaving innovations: a possible consequence of US federal laws.
- Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus.
- Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocar...
- The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses.
- Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment.
- Low rates of reporting commercial bias by physicians following online continuing medical education activities.
- Modest dietary reductions in blood cholesterol have important public health benefits.
- Aspirin use and risk of type 2 diabetes in apparently healthy men.
- Doing more good than harm: need for a cease fire.
- Statin-induced myopathy: hypothesis about randomized evidence and clinical impressions.
- Prevention of premature mortality among patients with schizophrenia: the need for primary prevention efforts in cardiovascular disease.
- Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.
- Lumbar spinal stenosis: can positional therapy alleviate pain?
- Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
- Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.
- Severe mental illness and risk of cardiovascular disease.
- The CHARM program: study design leads to findings of clinical and public health importance.
- Brain natriuretic peptide: clinical and research challenges.
- Obesity in childhood: introduction and general considerations.
- Series introduction and cardiovascular disease in patients with schizophrenia.
- Beta carotene supplementation and age-related maculopathy in a randomized trial of US physicians.
- Prevalence and clinical correlates of mitral annulus calcification in Hispanics and non-Hispanic whites.
- Aspirin and decreased adult-onset asthma: randomized comparisons from the physicians' health study.
- Descriptive and analytic epidemiologic studies to identify modifiable determinants of disparities in mortality rates between Blacks and Whites.
- Guidelines for management of high-risk African Americans with multiple cardiovascular risk factors: recommendations of an expert consensus panel.
- Learning how to reduce death rates in African American communities.
- Managing cardiovascular risk factors in high-risk African Americans.
- Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia.
- Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
- Response to letter to the editor by Dr Mackin.
- Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
- Sir Richard Doll, 1912 to 2005: a tribute and personal remembrance.
- Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
- Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study).
- N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
- Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines.
- Phenylpropanolamine and hemorrhagic stroke in the Hemorrhagic Stroke Project: a reappraisal in the context of science, the Food and Drug Administration, and the law.
- High-risk African Americans with multiple risk factors for cardiovascular disease: challenges in prevention, diagnosis, and treatment.
- Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial.
- Schizophrenia and increased risks of cardiovascular disease.
- Analgesic use and risk of subsequent hypertension in apparently healthy men.
- Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding.
- Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.
- Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.
- The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
- A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
- Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
- Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges.
- Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
- Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis.
- Terms and conditions: semantic complexity and aspirin resistance.
- Management of metabolic syndrome: aspirin.
- Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease.
- Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials.
- Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective...
- Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits.
- A trial of omega-3 fatty acids for prevention of hypertension.
- Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.
- Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and t...
- An update on clinical trials in pacing: is dual chamber pacing better?
- Hypertension: trends, risks, drug therapies and clinical challenges in African Americans.
- Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
- Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
- The ALLHAT-LLT and ASCOT-LLA trials: are the discrepancies more apparent than real?
- Occupational risk factors for selected cancers among African American and White men in the United States.
- An update on aspirin in the primary prevention of cardiovascular disease.
- Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.
- Analgesic use and change in kidney function in apparently healthy men.
- Inflammation in atherosclerosis: causal or casual? The need for randomized trials.
- Pacemaker mode selection: the evidence from randomized trials.
- Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested.
- A randomized trial of beta carotene and age-related cataract in US physicians.
- Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.
Schools
Weill Cornell Medical College
Doctors Specialties
- Preventive Medicine
Accepted Insurances
- MultiPlan PPO
- PHCS Network PPO
Awards
- Fellow (FACC)
Education
-
New York Presbyterian Hospital - Cornell Campus -
Weill Cornell Medical College of Cornell University
Helpful Reviews
Similar Doctors
|
|
Dr. Sheldon R. Forman, MD |
|
Dr. Kenneth L. Janson, MD
 This Doctor is OpenDoctor Recommended.
|